ArticleNature medicine2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07627568 (Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.), which is not on this map. Cited by 185 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed, 1 pooled it
12.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
Who cites it
185 citing papers in PubMed, 1 synthesis or guideline pooled it, 284 citations in OpenAlex.
- TKI Maintenance After Stem-Cell Transplantation forFrontiers in immunology · 2021Pooled it
- Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.Blood advances · 2023Trial
- Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.Bone marrow transplantation · 2022Trial
- Trial
- Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.JCI insight · 2019Trial
- Novel targeted therapy and cellular immunotherapy enabling allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia.Chinese medical journal · 2026Review
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.The Journal of clinical investigation · 2026Article
- FLT3 inhibition after transplantation: real-world evidence confirms common practice.Haematologica · 2026Article
- FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Current hematologic malignancy reports · 2026Review
- Article
- FLT3 inhibitor maintenance after allogeneic transplantation is associated with improved survival in FLT3-mutated AML: MRD-stratified evidence from an updated meta-analysis.Bone marrow transplantation · 2026Article
- Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.Blood advances · 2026Article
- Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.Blood research · 2026Article
- Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation.Blood immunology & cellular therapy · 2026Article
- Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- Efficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.European journal of haematology · 2026Article
- Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.Annals of hematology · 2026Article
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
125 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
130 authors at 20 institutions in 13 countries.
Nimitha R MathewDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Francis BaumgartnerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Lukas BraunDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
David O'SullivanMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Simone ThomasDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Miguel WaterhouseDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Tony A MüllerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Kathrin HankeDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Sanaz TaromiDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Petya ApostolovaDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Anna L IllertDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Wolfgang MelchingerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Sandra DuquesneDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Annette Schmitt-GraeffDepartment of Pathology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Lena OsswaldDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Kai-Li YanDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Arnim WeberDepartment of Medical Microbiology and Hygiene, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Sonia TuguesInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Sabine SpathInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Dietmar PfeiferDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Marie FolloDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Rainer ClausDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Christoph RummeltDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Hartmut BertzDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Ralph WäschDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Johanna HaagDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Andrea SchmidtsDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Michael SchultheissDepartment of Medicine II, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Dominik BettingerDepartment of Medicine II, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Robert ThimmeDepartment of Medicine II, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Evelyn UllrichDepartment for Children and Adolescents Medicine, Division of Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
Yakup TanriverDepartment of Medical Microbiology and Hygiene, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Giang Lam VuongDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
Renate ArnoldDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
Philipp HemmatiDepartment of Stem Cell Transplantation, Charité University Medicine Berlin, Berlin, Germany.
Dominik WolfDepartment of Hematology, University Medical Center Innsbruck, Austria.
Markus DitschkowskiDepartment of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
Cordula JilgDepartment of Urology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Konrad WilhelmDepartment of Urology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Christian LeiberDepartment of Urology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Sabine GerullDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Jörg HalterDivision of Hematology, University Hospital Basel, Basel, Switzerland.
Claudia LengerkeDivision of Hematology, University Hospital Basel, Basel, Switzerland.ORCID 0000-0001-5442-2805
Thomas PabstDepartment of Internal Medicine, Inselspital/Universitätsspital Bern, Bern, Switzerland.
Thomas SchroederDepartment of Hematology, Oncology and Clinical Immunology, Universitätsklinikum, Düsseldorf, Düsseldorf, Germany.
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, Universitätsklinikum, Düsseldorf, Düsseldorf, Germany.
Wolf RöslerDepartment of Hematology and Oncology, University of Erlangen, Erlangen, Germany.
Soroush DoostkamInstitute for Neuropathology, University of Freiburg, Freiburg, Germany.
Stephan MeckelDepartment of Neuroradiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Kathleen StablaDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany.
Stephan K MetzelderDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany.
Sebastian HalbachInstitute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University Medical Center Freiburg, University of Freiburg,Freiburg, Germany.ORCID 0000-0002-6827-8178
Tilman BrummerInstitute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University Medical Center Freiburg, University of Freiburg,Freiburg, Germany.
Zehan HuDepartment of Dermatology, University Medical Center, University of Freiburg, Freiburg, Germany.
Joern DengjelDepartment of Dermatology, University Medical Center, University of Freiburg, Freiburg, Germany.
Björn HackansonInterdisciplinary Cancer Center Augsburg (ICCA) II, Clinic for Internal Medicine, Augsburg, Germany.
Christoph SchmidInterdisciplinary Cancer Center Augsburg (ICCA) II, Clinic for Internal Medicine, Augsburg, Germany.
Udo HoltickDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Christof ScheidDepartment of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Alexandros SpyridonidisHematology Stem Cell Transplant Unit, School of Medicine, University of Patras, Patras, Greece.ORCID 0000-0003-3097-2532
Friedrich StölzelDepartment of Hematology and Oncology, Universitätsklinikum Carl Gustav Carus and Technischen Universität Dresden, Dresden, Germany.
Rainer OrdemannDepartment of Hematology and Oncology, Universitätsklinikum Carl Gustav Carus and Technischen Universität Dresden, Dresden, Germany.
Lutz P MüllerDepartment of Hematology and Oncology, Universitätsklinikum Halle, Halle, Germany.
Flore Sicre-de-FontbruneAssistance Publique-Hôpitaux de Paris, Hematology Stem Cell Transplantation, Saint Louis Hospital, Paris, France.
Gabriele IhorstClinical Trials Unit, Faculty of Medicine, University Medical Center, University of Freiburg, Freiburg, Germany.
Jürgen KuballDepartment of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jan E EhlertProQinase, Freiburg, Germany.
Daniel FegerProQinase, Freiburg, Germany.
Eva-Maria WagnerDepartment of Hematology and Oncology, Universitätsmedizin Mainz, Mainz, Germany.
Jean-Yves CahnClinique Universitaire Hématologie, Université Grenoble Alpes, Grenoble, France.
Jacqueline SchnellDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Florian KuchenbauerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Donald BunjesDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Ronjon ChakravertyCancer Institute, Royal Free Hospital, London, UK.
Simon RichardsonCancer Institute, Royal Free Hospital, London, UK.
Saar GillSmilow Translational Research Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Francis AyukDepartment of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Luca VagoUnit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy.
Fabio CiceriUnit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy.
Antonia M MüllerDepartment of Hematology, University Hospital Zurich, Zurich, Switzerland.
Takeshi KondoDepartment of Hematology, Hokkaido University, Sapporo, Japan.
Takanori TeshimaDepartment of Hematology, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-0941-271X
Susan KlaegerGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Bernhard KusterProteomics and Bioanalytics, Technische Universität München, Partner Site of the German Cancer Consortium, Freising, Germany.ORCID 0000-0002-9094-1677
Dennis Dong Hwan KimDepartment of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Daniel WeisdorfHematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Walter van der VeldenDepartment of Hematology, Radboud University, Nijmegen, the Netherlands.
Daniela DörfelMedizinische Klinik II, Universitätsklinikum Tübingen, Tübingen, Germany.
Wolfgang BethgeMedizinische Klinik II, Universitätsklinikum Tübingen, Tübingen, Germany.
Inken HilgendorfKlinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Andreas HochhausKlinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Geoffroy AndrieuxGerman Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
Melanie BörriesGerman Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
Hauke BuschGerman Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.ORCID 0000-0003-4763-4521
John MagenauDepartment of Hematology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Pavan ReddyDepartment of Hematology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Myriam LabopinEBMT Statistical Unit, Hôpital Saint Antoine Paris, Paris, France.
Joseph H AntinDana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, Massachusetts, USA.
Andrea S HendenBone Marrow Transplant Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Geoffrey R HillBone Marrow Transplant Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Glen A KennedyDepartment of Haematology, Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia.
Merav BarDivision of Blood and Marrow Transplantation, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA.
Anita SarmaDepartment of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Donal McLornanDepartment of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Ghulam MuftiDepartment of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Betul OranDivision of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, Texas, USA.
Katayoun RezvaniDivision of Bone Marrow Transplantation, MD Anderson Cancer Center, Houston, Texas, USA.
Omid ShahDivision of Blood and Marrow Transplantation, Stanford University Medical School, Stanford, California, USA.
Robert S NegrinDivision of Blood and Marrow Transplantation, Stanford University Medical School, Stanford, California, USA.
Arnon NaglerDivision of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Marco PrinzDepartment of Neuroradiology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Andreas BurchertInstitute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University Medical Center Freiburg, University of Freiburg,Freiburg, Germany.
Andreas NeubauerDepartment of Hematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany.
Dietrich BeelenDepartment of Urology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Andreas MackensenInstitute for Neuropathology, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-0685-4483
Nikolas von BubnoffDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Wolfgang HerrDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Burkhard BecherInstitute of Experimental Immunology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1541-7867
Gerard SociéAssistance Publique-Hôpitaux de Paris, Hematology Stem Cell Transplantation, Saint Louis Hospital, Paris, France.
Michael A CaligiuriOhio State University Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
Eliana RuggieroUnit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy.
Chiara BoniniUnit of Immunogenetics, Leukemia Genomics and Immunobiology, San Raffaele Scientific Institute, Milan, Italy.
Georg HäckerDepartment of Medical Microbiology and Hygiene, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Justus DuysterDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Jürgen FinkeDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Erika PearceMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.
Robert ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
University of Freiburg · DEVita-Salute San Raffaele University · ITCharité - Universitätsmedizin Berlin · DEKing's College Hospital NHS Foundation Trust · GBPhilipps University of Marburg · DEUniversity Hospital of Basel · CHUniversity Hospital Ulm · DEUniversity of Zurich · CHDüsseldorf University Hospital · DEGerman Cancer Research Center · DEHokkaido University · JPInserm · FRJena University Hospital · DEMax Planck Institute of Immunobiology and Epigenetics · DEQIMR Berghofer Medical Research Institute · AUStanford University · USThe Royal Free Hospital · GBThe University of Texas MD Anderson Cancer Center · USUniversität Hamburg · DEUniversitätsklinikum Tübingen · DE
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTrial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2MEnhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7MGVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9MCancer Research UK 20265European Research Council 681012NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA072669NHLBI NIH HHS R01 HL118979
Abstract
Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-year survival rate below 20%. We observed that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 production by FLT3-ITD
Indexed as
Activating Transcription Factor 4AnimalsCD8-Positive T-LymphocytesCellular Reprogrammingfms-Like Tyrosine Kinase 3Gene Expression Regulation, NeoplasticGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansInterferon Regulatory Factor-7Interleukin-15Leukemia, Myeloid, AcuteMiceSorafenibTandem Repeat SequencesTransplantation, HomologousActivating Transcription Factor 4ATF4 protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3IL15 protein, humanInterferon Regulatory Factor-7Interleukin-15IRF7 protein, humanSorafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07627568ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.